BS HH 002

Drug Profile

BS HH 002

Alternative Names: BS-HH-002; BS-HH-002.SA; HH-002

Latest Information Update: 28 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Hangzhou Bensheng Pharmaceutical
  • Class Alkaloids; Antineoplastics; Harringtonines; Small molecules
  • Mechanism of Action Activating transcription factor 3 inhibitors; Activating transcription factor inhibitors; Apoptosis stimulants; Janus kinase-2 inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Polycythaemia vera; Solid tumours

Most Recent Events

  • 28 Jul 2017 Chemical structure information added
  • 01 Apr 2017 BS HH 002 is still undergoing pre-clinical trials for Solid tumours and polycythaemia vera in USA
  • 01 Apr 2017 Pharmacodynamics data from preclinical trials in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top